2022
DOI: 10.19102/icrm.2022.13104
|View full text |Cite
|
Sign up to set email alerts
|

Does Cardiac Contractility Modulation Therapy Reduce Atrial Fibrillation Burden?

Abstract: Cardiac contractility modulation (CCM) is an implantable technology approved by the U.S. Food and Drug Administration and intended for heart failure patients without a cardiac resynchronization therapy indication. CCM leads to reduced heart failure hospitalizations and improvements in exercise tolerance and quality of life. There are a lack of data examining the impact of CCM therapy on atrial fibrillation (AF) burden. We report the case of a 65-year-old man with a history of paroxysmal AF, hypertension, hyper… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 3 publications
0
2
0
Order By: Relevance
“…Another important observation is the reduced volume and area of the left atrium. This could be caused by the reverse modelling of atrial myocytes, which decreases left atrial pressure, prevents left atrial remodelling and precipitates AF [4]. This case shows that additional investigation into the association between AF and CCM therapy is needed.…”
Section: Discussionmentioning
confidence: 95%
“…Another important observation is the reduced volume and area of the left atrium. This could be caused by the reverse modelling of atrial myocytes, which decreases left atrial pressure, prevents left atrial remodelling and precipitates AF [4]. This case shows that additional investigation into the association between AF and CCM therapy is needed.…”
Section: Discussionmentioning
confidence: 95%
“…Studies on combination therapies and long‐term use are also limited. The relationship between atrial fibrillation burden and CCM device implantation has not been explored, necessitating further investigation 76 . Future studies could improve treatment outcomes and expand the beneficiary population by combining CCM with multiple treatment regimens.…”
Section: Application Prospects and Disadvantagesmentioning
confidence: 99%